Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.86B

Market cap28.86B

Price-Earnings ratio

20.96

Price-Earnings ratio20.96

Dividend yield

—

Dividend yield—

Average volume

960.90K

Average volume960.90K

High today

$198.20

High today$198.20

Low today

$198.20

Low today$198.20

Open price

$196.45

Open price$196.45

Volume

2.38K

Volume2.38K

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $198.20. The company's market cap stands at 28.86B, with a P/E ratio of 20.96.

As of 2026-06-08, Biogen(BIIB) stock has fluctuated between $198.20 and $198.20. The current price stands at $198.20, placing the stock 0.0% above today's low and 0.0% off the high.

The Biogen(BIIB)'s current trading volume is 2.38K, compared to an average daily volume of 960.9K.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.

BIIB News

TipRanks 2h

Needham upgrades Biogen on pipeline potential, stabilizing core business

Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Biogen is entering a phase of eight Phase 3 readouts through 2029 amid an improved outl...

TipRanks 2h

Biogen upgraded to Buy from Hold at Needham

Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Simply Wall St 3d

Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story - simplywall.st

...

Analyst ratings

55%

of 38 ratings

Buy

55.3%

Hold

39.5%

Sell

5.3%

More BIIB News

TipRanks 3d

Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

TipRanks 4d

UCB, Biogen announce dapirolizumab pegol data at EULAR

UCB and Biogen (BIIB) announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology, or EULAR, 2026 Cong...

Simply Wall St 4d

Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen

In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosu...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.